Mode of action Product Candidate or Program Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3 / Pivotal
Cancer metabolism Tumor starvation eryaspase /GRASPA® (asparaginase) 2L Advanced PAC TRYbeCA-1
Hypersensitive ALL NOPHO IST
Advanced TNBC TRYbeCA-2
1L Advanced PAC  
erymethionase (Methionine-γ-Lyase) Solid Tumors  
Immune modulation Immuno-oncology Tolerance induction Solid tumors*  
Enzymes replacement Therapeutic enzymes Metabolic diseases  

ALL: acute lymphoblastic leukemia; PAC: pancreatic cancer; TNBC: triple-negative breast cancer; 1L: first line; 2L: second line; IST: Investigator-sponsored trial; NOPHO: Nordic Society of Paediatric Haematology and Oncology; * Développé par SQZ Biotech